173 related articles for article (PubMed ID: 21345146)
1. CYLD: a deubiquitination enzyme with multiple roles in cancer.
Massoumi R
Future Oncol; 2011 Feb; 7(2):285-97. PubMed ID: 21345146
[TBL] [Abstract][Full Text] [Related]
2. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin chain cleavage: CYLD at work.
Massoumi R
Trends Biochem Sci; 2010 Jul; 35(7):392-9. PubMed ID: 20347313
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
5. [CYLD deubiquitinase as a recurrent target in oncogenic processes].
Bonnet M; Courtois G
Med Sci (Paris); 2011; 27(6-7):626-31. PubMed ID: 21718647
[TBL] [Abstract][Full Text] [Related]
6. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling.
Massoumi R; Chmielarska K; Hennecke K; Pfeifer A; Fässler R
Cell; 2006 May; 125(4):665-77. PubMed ID: 16713561
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
Courtois G
Cell Mol Life Sci; 2008 Apr; 65(7-8):1123-32. PubMed ID: 18193168
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of CYLD in human colon and hepatocellular carcinomas.
Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK
Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947
[TBL] [Abstract][Full Text] [Related]
9. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.
Komander D; Lord CJ; Scheel H; Swift S; Hofmann K; Ashworth A; Barford D
Mol Cell; 2008 Feb; 29(4):451-64. PubMed ID: 18313383
[TBL] [Abstract][Full Text] [Related]
10. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
11. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
12. Cylindromatosis--A Protective Molecule against Liver Diseases.
Hellerbrand C; Massoumi R
Med Res Rev; 2016 Mar; 36(2):342-59. PubMed ID: 26763122
[TBL] [Abstract][Full Text] [Related]
13. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
14. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control.
Massoumi R; Paus R
Bioessays; 2007 Dec; 29(12):1203-14. PubMed ID: 18008375
[TBL] [Abstract][Full Text] [Related]
15. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells.
Deng LL; Shao YX; Lv HF; Deng HB; Lv FZ
Neoplasma; 2012; 59(1):18-29. PubMed ID: 22017589
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
Kobayashi T; Masoumi KC; Massoumi R
Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
[TBL] [Abstract][Full Text] [Related]
17. The tumor suppressor CYLD controls the function of murine regulatory T cells.
Reissig S; Hövelmeyer N; Weigmann B; Nikolaev A; Kalt B; Wunderlich TF; Hahn M; Neurath MF; Waisman A
J Immunol; 2012 Nov; 189(10):4770-6. PubMed ID: 23066153
[TBL] [Abstract][Full Text] [Related]
18. Mutated cylindromatosis gene affects the functional state of dendritic cells.
Bros M; Dexheimer N; Besche V; Masri J; Trojandt S; Hövelmeyer N; Reissig S; Massoumi R; Grabbe S; Waisman A; Reske-Kunz AB
Eur J Immunol; 2010 Oct; 40(10):2848-57. PubMed ID: 20836156
[TBL] [Abstract][Full Text] [Related]
19. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
20. Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation.
Martinez-Forero I; Rouzaut A; Palazon A; Dubrot J; Melero I
Clin Cancer Res; 2009 Nov; 15(22):6751-7. PubMed ID: 19887490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
